About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Cardiovascular Effects of CART Cell Therapy | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT04026737

Cardiovascular Effects of CART Cell Therapy

This is an observational study aiming to prospectively define the rate of occurrence, natural history and progression of cardiac dysfunction in adults, and to identify the patients at high risk of dev...

Lead sponsor: Abramson Cancer Center at Penn Medicine•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Abramson Cancer Center at Penn Medicine

Patients have echo, blood draw, and QoL survey prior to CART infusion, then 2 days, 1 week, 1 month and 6 months following CART infusion. If patients experiences CRS, study team acquires echo within 72 hours of onset. As part of an optional substudy, patients wear an event monitor for 10 days, starting day of CART infusion.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•At least 18 years of age
•Diagnosed with CD19+ malignancy undergoing treatment with CART cells

Exclusion Criteria

•Unable to provide informed consent

Related studies

RECRUITINGEARLY Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690 · Acute Lymphoblastic Leukemia

RECRUITINGPhase 2

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT04570423 · Solid Tumors, Lymphoma

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

RECRUITINGPhase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, and more

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 9, 2026Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment44

Start dateJul 2019

Last updatedFeb 9, 2026

Condition

Leukemia Lymphoma Cardiotoxicity Risk Factor, Cardiovascular Immunotherapy

Locations shown

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions